Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 80.6 kDa. The protein migrates as 100-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human M-CSF R Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human M-CSF Protein, His Tag (Cat. No. MCF-H5247) at 5 μg/mL (100 μL/well) can bind Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) with a linear range of 0.1-4 ng/mL (QC tested).
Immobilized Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-34 Protein, His,Avitag (Cat. No. IL4-H82E5) with a linear range of 0.2-10 ng/mL (Routinely tested).
Human M-CSF Protein, His Tag (Cat. No. MCF-H5247) captured on CM5 Chip via anti-His antibody can bind Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) with an affinity constant of 1.9 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Loaded Biotinylated Human M-CSF Protein, His,Avitag (Cat. No. MCF-H82E6) on SA Biosensor, can bind Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) with an affinity constant of 24.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) on Protein A Biosensor, can bind Human M-CSF Protein, His Tag (Cat. No. MCF-H5247) with an affinity constant of 0.365 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors | Details |
pacritinib citrate | SB-1518; ONX-0803 | Approved | S*BIO Pte Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Cti Biopharma Corp | 2022-02-28 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Sarcoma, Kaposi; Thrombocytopenia; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Lymphoma, T-Cell, Peripheral; Castleman Disease; Primary Myelofibrosis; Coronavirus Infections; Lymphoma, Mantle-Cell; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Myelodysplastic Syndromes; Polycythemia Vera; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia | Details |
Surufatinib | HMPL-012 | Approved | Hutchison Medipharma Ltd | 苏泰达, SULANDA | Mainland China | Neuroendocrine Tumors | Hutchison Medipharma Ltd | 2020-12-29 | Solid tumours; Biliary Tract Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Sarcoma; Bile Duct Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Appendiceal Neoplasms; Carcinoma, Neuroendocrine | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; GB-102; PNU-290940; SU-011248-L-malate salt; PHA-290940; SU-010398; SU-11248 | Approved | Pfizer Inc | 索坦, Sutent | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Solid tumours; Fibromatosis, Aggressive; Ovarian Neoplasms; Kidney Neoplasms; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Leukemia, Myeloid, Accelerated Phase; Leukemia; Fibrosarcoma; Teratoma; Liver Neoplasms; Ependymoma; Lymphoma, T-Cell, Peripheral; Intestinal Neoplasms; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Hemangioblastoma; Carcinoma, Islet Cell; Carcinoma; Pheochromocytoma; Stomach Neoplasms; Pelvic Neoplasms; Esophageal Neoplasms; Leukemia, Hairy Cell; Polycythemia Vera; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Ovarian Epithelial; Glioblastoma; Neurofibromatoses; Small Cell Lung Carcinoma; Adenoma, Islet Cell; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Myelodysplastic Syndromes; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Carcinoma, Papil | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Neurofibrosarcoma; Giant Cell Tumors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neurofibroma, Plexiform; Sarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours; Breast Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Pancreatic Neoplasms; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Giant Cell Tumor of Tendon Sheath | Details |
Mirimostim | P-100; CSF-HU | Approved | Jcr Pharmaceuticals Co Ltd | Costilate, Leukoprol | Japan | Neutropenia | Jcr Pharmaceuticals Co Ltd | 1991-01-01 | Neutropenia | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vimseltinib | DCC-3014 | Phase 3 Clinical | Deciphera | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular; Neoplasms | Details |
Chiauranib | CS-2164; CS2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Solid tumours; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Sarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular | Details |
Pimicotinib | ABSK-021 | Phase 3 Clinical | ABbisko Therapeutics Co Ltd | Giant Cell Tumor of Tendon Sheath; Solid tumours; Synovitis, Pigmented Villonodular; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Neoplasms; Graft vs Host Disease; Sarcoma; Lung Neoplasms; Amyotrophic Lateral Sclerosis | Details |
Emactuzumab | RG-7155; 6FY6EI1X8R; RO-5509554 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Head and Neck Neoplasms; Carcinoma; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell | Details |
Recombinant human GM-CSF oncolytic herpes simplex virus type 2 (OH2) | BS-001; BS001; oHSV-2; OH-2; OH2 | Phase 3 Clinical | Wuhan Binhui Biotechnology Co Ltd | Central Nervous System Neoplasms; Melanoma; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Sarcoma; Liver Diseases; Solid tumours; Digestive System Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Pancreatic Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Head and Neck Neoplasms | Details |
Tinengotinib | TT-00420; TT 00420; TT00420 | Phase 3 Clinical | TransThera Sciences (Nanjing) Inc | Biliary Tract Neoplasms; Solid tumours; Kidney Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Thyroid Neoplasms; Gallbladder Neoplasms | Details |
LY-3022855 | IMC-CS4; LY-3022855 | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis; Melanoma | Details |
Simmitinib hydrochloride | SOMCL-15-290 | Phase 2 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours; Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
Cabiralizumab | FPA-008; ONO-4687; BMS-986227 | Phase 2 Clinical | Five Prime Therapeutics Inc | Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Giant Cell Tumor of Tendon Sheath; Lymphoma, T-Cell, Peripheral; Carcinoma, Renal Cell; Synovitis, Pigmented Villonodular; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Arthritis, Rheumatoid; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
AMG-820 | AMG-820 | Phase 2 Clinical | Amgen Inc | Solid tumours; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
C-019199 | C019199 | Phase 2 Clinical | Fujian Haixi Pharmaceuticals Co Ltd | Solid tumours | Details |
Edicotinib | PRV-6527; JNJ-244; JNJ-40346527-AAC-G-002; JNJ-40346527; JNJ-527 | Phase 2 Clinical | Johnson & Johnson | Arthritis, Rheumatoid; Hodgkin Disease; Prostatic Neoplasms; Alzheimer Disease; Cognitive Dysfunction; Leukemia, Myeloid, Acute; Crohn Disease | Details |
Sotuletinib | BLZ-945 | Phase 2 Clinical | Novartis Pharma Ag, Celgene Corp | Solid tumours; Amyotrophic Lateral Sclerosis | Details |
Elzovantinib | TPX-0022 | Phase 2 Clinical | Turning Point Therapeutics Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
[11C]CPPC | Phase 2 Clinical | Johns Hopkins University | Post-Acute COVID-19 Syndrome; Amyotrophic Lateral Sclerosis | Details | |
AMB-05X | AMB-05X | Phase 2 Clinical | Amgen Inc | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular; Idiopathic Pulmonary Fibrosis; Testicular Neoplasms | Details |
Q-702 | Q-702 | Phase 2 Clinical | Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details |
PMI-04 | Phase 1 Clinical | Precision Molecular Inc | Nerve Degeneration | Details | |
APL-102 | APL-102; CBT-102 | Phase 1 Clinical | Apollomics Inc | Solid tumours | Details |
Pamufetinib | TAS-115 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | Neoplasms | Details |
JDB-383 | JDB-383 | Phase 1 Clinical | Shanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd | Giant Cell Tumor of Tendon Sheath | Details |
HMPL-653 | HMPL-653 | Phase 1 Clinical | Hutchison Medipharma Ltd | Giant Cell Tumor of Tendon Sheath; Solid tumours; Testicular Neoplasms | Details |
ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Caflanone | FBL-03G | Phase 1 Clinical | Flavocure Biotech Inc | Pancreatic Neoplasms | Details |
Nintedanib Solution for Inhalation | AP02; AP-02 | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis | Details |
EI-1071 | EI-1071; FB-1071 | Phase 1 Clinical | Elixiron Immunotherapeutics Inc | Giant Cell Tumor of Tendon Sheath; Alzheimer Disease; Nervous System Diseases; Amyotrophic Lateral Sclerosis | Details |
SYHA-1817 | SYHA-1817 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell | Details |
TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
BC-006 | BC-006; BC006 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Giant Cell Tumor of Tendon Sheath | Details |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
SYHA-1813 | SYHA1813 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Runshi Pharmaceutical Technology Co Ltd | Giant Cell Tumor of Tendon Sheath; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Gliosarcoma; Colorectal Neoplasms; Brain metastases; Thyroid Neoplasms; Lung Neoplasms; Glioma | Details |
This web search service is supported by Google Inc.